KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Jia Zhong, Kailun Fei, Lin Wu, Baolan Li, Zhijie Wang, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv, Jianhua Shi, Jianjin Huang, Shaozhang Zhou, Baohui Han, Guogui Sun, Qisen Guo, Youxin Ji, Xiaoli Zhu, Sheng Hu, Wei Zhang, Qiming Wang, Yuming Jia, Ziping Wang, Yong Song, Jingxun Wu, Meiqi Shi, Xingya Li, Zhigang Han, Yunpeng Liu, Zhuang Yu, An-Wen Liu, Xiuwen Wang, Caicun Zhou, Diansheng Zhong, Liyun Miao, Zhihong Zhang, Hui Zhao, Jun Yang, Dong Wang, Yingyi Wang, Qiang Li, Xiaodong Zhang, Mei Ji, Zhenzhou Yang, Jiuwei Cui, Beili Gao, Buhai Wang, Hu Liu, Lei Nie, Mei He, Shi Jin, Wei Gu, Yongqian Shu, Tong Zhou, Jian Feng, Xinmei Yang, Cheng Huang, Bo Zhu, Yu Yao, Sheng Yao, Jianjun Yu, Shang Li Cai, Yiran Cai, Jiachen Xu, Wei Zhuang, Xianmin Luo, Jianchun Duan, Jie Wang

Signal Transduct Target Ther 9(1) 369

PMID39715755
PMCIDPMC11666711
DOI10.1038/s41392-024-02087-6
发表日期2024-12-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

A randomized double-blind phase 3 trial (CHOICE-01, NCT03856411) demonstrated that combining toripalimab with chemotherapy substantially improves progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients without pretreatment. This study presents the prespecified final analysis of overall survival (OS) and biomarkers utilizing circulating tumor DNA (ctDNA) and tissue-based sequencing. Additionally, the analysis revealed a higher median overall survival (OS, 23.8 months) in the toripalimab group than that in the control group (17.0 months). (HR = 0.69, 95%CI: 0.57-0.93, nominal P = 0.01). This survival benefit was particularly notable in the non-squamous subgroup. As the first phase 3 study to perform both baseline tissue whole-exome sequencing (WES) and peripheral blood ctDNA testing, we investigated efficacy predictive biomarkers based on both tissue and ctDNA, Genomic sequencing of ctDNA showed high concordance with tumor tissue independently confirmed that individuals exhibiting a high tumor mutational burden, as well as mutations in the FA-PI3K-Akt and IL-7 signaling pathways benefited more from the toripalimab treatment. Furthermore, a ctDNA response observed on cycle 3 day 1, was associated with improved clinical outcomes for patients treated with the combination therapy. In conclusion, Toripalimab plus chemotherapy yields significant improvements in OS as a first-line treatment. The study highlights the utility of ctDNA as a proxy for tumor tissue, providing novel prospects for predicting efficacy of immuno-chemotherapy through continuous ctDNA monitoring.

KM 提取结果

3 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2 OS in the Intention-to-Treat Population. a The Kaplan-Meier estimates of OS comparing the toripalimab plus chemotherapy group with the placebo plus chemotherapy group as first-line treatment for patients with advanced NSCLC. Censored patients are marked with “┃” in the graph. Numbers of patients at risk at indicated time points are shown below the x-axis. Number of events, median OS, 1-, 2- and 3-year OS rates, and stratified hazard ratio for death are shown to the right of Kaplan-Meier curves. b Overall survivals in key subgroups. All hazard ratios were computed using the Cox proportional hazards model. All P values were two-sided with no adjustment of multiplicity. The P values of comparing the Kaplan-Meier curves were computed using the log-rank test stratified by the baseline PD-L1 expression status, histology, and smoking status. The P values of testing the interaction of the subgroup variables with the treatment were computed using the Cox proportional hazards regression model with the treatment group, the subgroup variable and their interaction as the covariates. HR, hazard ratio; NA, not available; NSCLC, non–small-cell lung cancer; PD-L1, programmed death ligand-1; PFS, progression-free survival

A

OS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
B

OS

Fig. 2 · Panel B

quality_warning 待 EXE 对齐 预期 12 条 已提取 5 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 12 条,实际恢复 5 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Fig. 3

Fig. 3 The concordance of mutational landscape between ctDNA and tissue WES data. a The matched frequency of top mutated genes derived from blood-based ctDNA and tumor WES data, ordered by the prevalence rate in ctDNA. b The mutations of top mutated genes between ctDNA profiling and matched tissue were strongly concordant. c The Kaplan-Meier estimates of PFS stratified by bTMB status in ITT patients. Low ctDNA shedders (<5% tumor fraction) were removed to ensure the specimens had subclone mutations adequately captured by the sequencing assay. ctDNA, circulating tumor DNA; WES, whole exome sequencing; TMB, tumor mutational burden; bTMB, blood tumor mutational burden; PFS, progression-free survival; ITT, intention-to-trea;JS001: toripalimab

C

PFS

Fig. 3 · Panel C

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:off origin start曲线 3:extreme jump
查看结果
KM Figure2 个面板

Fig. 4

Fig. 4 Analyses of ctDNA dynamics at C3D1. a Distribution of tumor load changes in the two arms and association with the best overall response. Tumor load dynamics were categorized into four groups: Negative in both baseline and C3D1 timepoints(BothNeg), Decrease at C3D1(Decrease), Increase at C3D1(Increase), and Reduction to undetectable levels at C3D1(ToNeg). The decrease in the toripalimab arm was more prominent. A higher percentage of patients exhibiting partial response was also observed in the toripalimab group. b Tumor load, as estimated by tumor fraction in blood, decreased at C3D1 for both toripalimab and placebo arms. Response of ctDNA at C3D1 is predictive of PFS ( c ) and OS ( d ) in ITT patients. The ctDNA response was defined as >85% reduction of tumor load from C1D1 or no detection of ctDNA at C3D1. ctDNA, circulating tumor DNA, ITT, intention-to-treat. JS001: toripalimab

C

Progression-Free Survival

Fig. 4 · Panel C

complete 待 EXE 对齐 预期 6 条 已提取 6 条

Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Overall Survival

Fig. 4 · Panel D

quality_warning 待 EXE 对齐 预期 6 条 已提取 5 条

Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 5 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 CONSORT diagram of the CHOICE-01 study. Between April 2, 2019 and August 5, 2020, 835 patients with advanced non-small-cell lung cancer were screened for eligibility from 59 centers across China. 465 were enrolled and randomly assigned in a 2:1 ratio to the toripalimab plus standard first-line chemotherapy group ( n = 309) or the placebo plus standard first-line chemotherapy group ( n = 156). By the cutoff date of August 31, 2022, one patient from the toripalimab group and seven patients from the placebo group were still under study treatment. Among the patients who ended study treatment, 127 patients from the toripalimab group and 45 patients from the placebo group were still under study. Among patients in the placebo group, 81 crossed over to toripalimab treatment after disease progression. ITT, intention-to-treat; PPS, per protocol set; SS, safety set
非 KM Figure